The role of comparative observational studies
The NEJM and The Lancet on 06 June retracted two non-randomised comparative studies, of anti-hypertensive therapy and of excess mortality from hydroxychloroquine or chloroquine with or without a macrolide for the treatment of COVID-19, respectively.
WHO reported on 03 June that the hydroxychloroquine arm of the SOLIDARITY trial will continue following review by the data monitoring committee.
OXON leads a group of international European academics and clinicians to conduct the ‘RAPID COVID-19′ research programme in hospitalised COVID-19 patients:
- Retrospective cohort analyses of a large dataset from a network of hospitals to evaluate the clinical effectiveness and safety of medications and determine prognostic factors.
- Real-time systematic reviews and meta-analyses of non-randomised treatment comparisons.
- Comparison of treatment effects in RCTS and non-randomised studies.
Our research is detailed in international registers. Our research is driven by an international study team which includes an eminent Professor of Medical Statistics who is a member of the DISCOVERY trial Data Monitoring Committee.
We would welcome collaboration, including sharing our experience with companies involved in COVID-19
OXON conducts data collection (retrospective chart review, prospective studies and registries), secondary data and hybrid observational studies and pragmatic trials for safety, market access and drug development in Europe (+ USA, Asia and elsewhere) in all major therapy areas, orphan conditions and pregnancy.
